Updated on 5 October 2012
Anaphore is now RuiYi
Singapore: Anaphore changed its corporate name to RuiYi. As part of the company's shift in strategy to the R&D of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai.
"RuiYi's new direction will enable us to focus on building our capabilities in Shanghai as we collaborate with a number of innovative drug discovery and development companies to advance our technology," commented Mr Paul Grayson, president and CEO, RuiYi.
RuiYi also announced today that it has added three key members to its management team to guide its GPCR drug discovery efforts, including Dr Chris Song, as director of operations; Dr Shouhua (Josh) Xiao, as senior director of protein technology; and Dr Lei Shi, as director of antibody discovery.